Allen D. Seftel, MD; Geoffrey Hackett, MD
Potential Conflicts of Interest: Dr. Seftel: Board membership: Journal of Urology; Consultancy: Lilly, Endo, Auxilium, Abbott, Actient. Dr. Hackett: Payment for lectures including service on speakers bureaus: Pfizer, Lilly.
Seftel A., Hackett G.; Effects of Testosterone Replacement on Response to Sildenafil Citrate. Ann Intern Med. 2013;158:569. doi: 10.7326/0003-4819-158-7-201304020-00017
Download citation file:
Published: Ann Intern Med. 2013;158(7):569.
TO THE EDITOR:
Spitzer and colleagues' article (1) purports to show that, in men with erectile dysfunction (ED), adding testosterone replacement therapy to a successful course of phosphodiesterase type 5 (PDE5) inhibitor therapy (oral sildenafil) to further augment erectile function was not beneficial. The International Index of Erectile Function's (IIEF's) erectile function domain (EFD) was used to assess baseline and posttreatment erectile function, with a mean baseline EFD score of 12.2 for the testosterone group and 12.0 for the placebo group. A score of 12.0 places these men in the “moderate” ED category (2).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only